Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of GR1501 in chronic moderate-to-severe plaque psoriasis
CTR20210246Phase 3Completed
- Sponsor
- Zhixiang Jintai
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of xeligekimab in plaque psoriasis, sponsored by Zhixiang Jintai. Started Mar 2021; status: completed.
02
Drugs
xeligekimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20210246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210246.